BACKGROUND: The optimal duration of dual antiplatelet therapy (DAPT) after implantation of drug-eluting coronary stents remains undetermined. We aimed to test whether 6-month DAPT would be noninferior to 12-month DAPT after implantation of drug-eluting stents. METHODS AND RESULTS: We randomly assigned 1443 patients undergoing implantation of drug-eluting stents to receive 6- or 12-month DAPT (in a 1:1 ratio). The primary end point was a target vessel failure, defined as the composite of cardiac death, myocardial infarction, or ischemia-driven target vessel revascularization at 12 months. Rates of target vessel failure at 12 months were 4.8% in the 6-month DAPT group and 4.3% in the 12-month DAPT group (the upper limit of 1-sided 95% confid...
Background: Optimal duration of dual antiplatelet therapy (DAPT) in patients with diabetes mellitus ...
Objective To show that limiting dual antiplatelet therapy (DAPT) to six months in patients with even...
IMPORTANCE: Despite antirestenotic efficacy of coronary drug-eluting stents (DES) compared with bare...
Background: The optimal duration of dual antiplatelet therapy (DAPT) following drugeluting stent (DE...
9siBackground The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary i...
Objective To show that limiting dual antiplatelet therapy (DAPT) to six months in patients with even...
BACKGROUND: The optimal duration of dual antiplatelet therapy (DAPT) following second-generation dru...
BACKGROUND: The optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) ...
AbstractBackgroundThe appropriate duration of dual antiplatelet therapy (DAPT) with aspirin and a th...
OBJECTIVES: The aim of this study was to investigate whether a 6-month dual-antiplatelet therapy (DA...
ObjectivesThe goal of this study was to evaluate shorter duration (3 months) dual antiplatelet thera...
AimWe sought to determine whether the optimal dual antiplatelet therapy (DAPT) duration after drug-e...
18siObjective To show that limiting dual antiplatelet therapy (DAPT) to six months in patients with ...
BACKGROUND The optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES...
Objective To show that limiting dual antiplatelet therapy (DAPT) to six months in patients with even...
Background: Optimal duration of dual antiplatelet therapy (DAPT) in patients with diabetes mellitus ...
Objective To show that limiting dual antiplatelet therapy (DAPT) to six months in patients with even...
IMPORTANCE: Despite antirestenotic efficacy of coronary drug-eluting stents (DES) compared with bare...
Background: The optimal duration of dual antiplatelet therapy (DAPT) following drugeluting stent (DE...
9siBackground The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary i...
Objective To show that limiting dual antiplatelet therapy (DAPT) to six months in patients with even...
BACKGROUND: The optimal duration of dual antiplatelet therapy (DAPT) following second-generation dru...
BACKGROUND: The optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) ...
AbstractBackgroundThe appropriate duration of dual antiplatelet therapy (DAPT) with aspirin and a th...
OBJECTIVES: The aim of this study was to investigate whether a 6-month dual-antiplatelet therapy (DA...
ObjectivesThe goal of this study was to evaluate shorter duration (3 months) dual antiplatelet thera...
AimWe sought to determine whether the optimal dual antiplatelet therapy (DAPT) duration after drug-e...
18siObjective To show that limiting dual antiplatelet therapy (DAPT) to six months in patients with ...
BACKGROUND The optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES...
Objective To show that limiting dual antiplatelet therapy (DAPT) to six months in patients with even...
Background: Optimal duration of dual antiplatelet therapy (DAPT) in patients with diabetes mellitus ...
Objective To show that limiting dual antiplatelet therapy (DAPT) to six months in patients with even...
IMPORTANCE: Despite antirestenotic efficacy of coronary drug-eluting stents (DES) compared with bare...